Acyloxyacyl Hydrolase is a Host Determinant of Gut Microbiome-Mediated Pelvic Pain

Abstract

Dysbiosis of gut microbiota is associated with many pathologies, yet host factors modulating microbiota remain unclear. Interstitial cystitis/bladder pain syndrome (IC/BPS or “IC”) is a debilitating condition of chronic pelvic pain often with co-morbid urinary dysfunction and anxiety/depression, and recent studies find fecal dysbiosis in IC/BPS patients. We previously identified the locus encoding acyloxyacyl hydrolase, Aoah, as a modulator of pelvic pain severity in a murine IC/BPS model. AOAH-deficient mice spontaneously develop rodent correlates of pelvic pain, increased responses to induced pelvic pain models, voiding dysfunction, and anxious/depressive behaviors. Here, we report that AOAH-deficient mice exhibit dysbiosis of GI microbiota. AOAH-deficient mice exhibit an enlarged cecum, a phenotype long associated with germ-free rodents, and reduced trans-epithelial electrical resistance consistent with a “leaky gut” phenotype. AOAH-deficient ceca showed altered gene expression consistent with inflammation, Wnt signaling, and urologic disease. 16S rRNA sequencing of stool revealed altered microbiota in AOAH-deficient mice, and GC-MS identified altered metabolomes. Co-housing AOAH-deficient mice with wild type mice resulted in converged microbiota and altered predicted metagenomes. Co-housing also abrogated the pelvic pain phenotype of AOAH-deficient mice, which was corroborated by oral gavage of AOAH-deficient mice with stool slurry of wild type mice. Converged microbiota also alleviated comorbid anxiety-like behavior in AOAH-deficient mice. Oral gavage of AOAH-deficient mice with anaerobes cultured from IC/BPS stool resulted in exacerbation of pelvic allodynia. Together, these data indicate that AOAH is a host determinant of normal gut microbiota, and the dysbiosis associated with AOAH deficiency contributes to pelvic pain. These findings suggest that the gut microbiome is a potential therapeutic target for IC/BPS.

Microbiome First Approaches in Pain Prevention and Management

“…Examples are included that focus on pain associated with gastrointestinal issues (ulcerative colitis and irritable bowel), osteoarthritis, probiotics and headaches, post-surgical pain, neurologic and visceral pain, menopausal status, the risk-benefit role of opioids, the connections between microbiota and microglia activation, and gut microbiota as pertains to pain hypersensitivity vs. tolerance. While a variety of microbiome studies are described within the review articles in Table 1, the most recent preclinical and clinical trials from the past 2-3 years are highlighted in Table 2 [52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71]. Several areas of activity are notable.…”

Unraveling the microbial puzzle: exploring the intricate role of gut microbiota in endometriosis pathogenesis

“…EMs lesions mainly occur in the pelvic cavity, which is also a container for holding the small intestine and colorectum. The intestine contains a large number of gut microbiota, which exert an important role in maintaining pelvic stability (Rahman-Enyart et al, 2021). Several studies have confirmed the idea that gut microbiota is involved in many inflammatory, immune, and proliferative diseases (Chadchan et al, 2021;Jiang et al, 2021;Shan et al, 2021).…”